Video

Dr. Eyre Discusses Venetoclax Monotherapy in MCL

Toby Eyre, MBChB, MRCP, consultant hematologist at Oxford University Hospitals NHS Foundation Trust, discusses venetoclax (Venclexta) monotherapy in patients with mantle cell lymphoma.

Toby Eyre, MBChB, MRCP, consultant hematologist at Oxford University Hospitals NHS Trust, discusses venetoclax (Venclexta) monotherapy in patients with mantle cell lymphoma (MCL).

Patients with relapsed/refractory MCL have a poor prognosis, with an approximate overall survival of 2 years, says Eyre. Even with the success of BTK inhibitors, many patients relapse, creating an area of unmet need. In a study of patients with poor-risk relapsed/refractory MCL previously treated with a BTK inhibitor, venetoclax monotherapy induced an overall response rate of 60%. Of the responders, 20% had a complete response.

These data come from the UK Medicines and Healthcare Products Regulatory Agency compassionate use scheme, says Eyre. The majority of these patients received ibrutinib (Imbruvica), but some had received other BTK inhibitors while on a clinical trial. These 20 patients went on to received venetoclax monotherapy, but the efficacy data was not collected in the post-BTK inhibitor setting until this study.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity